GRCE vs. VTYX, NBTX, CLYM, MCRB, SAVA, SGMT, TSVT, LPTX, RENB, and IGMS
Should you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Ventyx Biosciences (VTYX), Nanobiotix (NBTX), Climb Bio (CLYM), Seres Therapeutics (MCRB), Cassava Sciences (SAVA), Sagimet Biosciences (SGMT), 2seventy bio (TSVT), Leap Therapeutics (LPTX), Renovaro (RENB), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical preparations" industry.
Grace Therapeutics vs.
Ventyx Biosciences (NASDAQ:VTYX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings.
Ventyx Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.
Ventyx Biosciences received 31 more outperform votes than Grace Therapeutics when rated by MarketBeat users.
Grace Therapeutics is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.
97.9% of Ventyx Biosciences shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 18.2% of Ventyx Biosciences shares are owned by company insiders. Comparatively, 13.5% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Grace Therapeutics' return on equity of -18.09% beat Ventyx Biosciences' return on equity.
Ventyx Biosciences presently has a consensus target price of $10.00, suggesting a potential upside of 366.20%. Given Ventyx Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Ventyx Biosciences is more favorable than Grace Therapeutics.
In the previous week, Ventyx Biosciences had 12 more articles in the media than Grace Therapeutics. MarketBeat recorded 12 mentions for Ventyx Biosciences and 0 mentions for Grace Therapeutics. Ventyx Biosciences' average media sentiment score of 0.80 beat Grace Therapeutics' score of 0.00 indicating that Ventyx Biosciences is being referred to more favorably in the media.
Summary
Ventyx Biosciences beats Grace Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Grace Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Grace Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GRCE) was last updated on 1/22/2025 by MarketBeat.com Staff